Talipexole
From Wikipedia, the free encyclopedia
 |
|
 |
|
| Clinical data | |
|---|---|
| Trade names | Domin |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration |
Oral |
| ATC code | none |
| Legal status | |
| Legal status |
|
| Identifiers | |
|
|
| Synonyms | Alefexole |
| CAS Number | 36085-73-1  |
| PubChem (CID) | 5374 |
| IUPHAR/BPS | 5442 |
| ChemSpider | 5181 |
| UNII | 7AM2J46Z1Y |
| ChEMBL | CHEMBL1289023 |
| Chemical and physical data | |
| Formula | C10H15N3S |
| Molar mass | 209.31 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
 (what is this?) (verify) |
|
Talipexole (B-HT920, Domnin) is a dopamine agonist that is marketed as a treatment for Parkinson's Disease in Japan by Boehringer Ingelheim; it was introduced in 1996.[1] As of December 2014 it was not approved for marketing in the US nor in Europe.[2]
Talipexole is a D2 dopamine receptor agonist and interacts both pre- and post-synaptic receptors. It also is an α2-adrenergic agonist.[3]
The main side effects are drowsiness, dizziness, hallucinations and minor gastrointestinal complaints.[3] In 2008 the Japanese Ministry of Health, Labour, and Welfare mandated that Boehringer add a warning to the label concerning the risk of sudden onset of sleep.[4]:15
References[edit]
- ^ PharmaLetter 22 July 1996 First Launch In Japan For Talipexole
- ^ EvaluatePharma Database. Page accessed 9 December 2014
- ^ a b Benkert O, et al. Dopamine agonists in schizophrenia: a review. Eur Neuropsychopharmacol. 1995;5 Suppl:43-53. PMID 8775758
- ^ Japanese Ministry of Health, Labour and Welfare March 2008 Pharmaceuticals and Medical Devices Safety Information No. 245
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
